黄芪合剂防治化疗性骨髓抑制的实验研究

A Laboratory Study on Astragalus Membranaceus Mistura in the Prophylaxis and Treatment of Myelosuppression Caused by Cancer Chemotherapy

自拟黄芪合剂处方，以荷Ｓ１８０小鼠为观察对象，探讨黄芪合剂对癌化疗药物骨髓抑制的影响。通过外周血象的ＲＰＭＩ变化，淋巴细胞转化实验，中性红染料摄入法检测巨噬细胞吞噬功能，以及透射电镜对骨髓造血微环境超微结构进行观察。结果：黄芪合剂对骨髓造血功能有保护作用，外周血白细胞及血小板计数与其它组对比有显著性差异（Ｐ＜０．０１）；黄芪合剂明显提升淋巴细胞转化率及巨噬细胞吞噬功能，（Ｐ＜０．０１）；对巨噬细胞及网状内皮细胞等基质细胞有保护作用。

he purpose of this study was to evaluate the effect of Astragalus membranaceus mistura on the chemotherapyassociated toxicity. Astragalus membranaceus mistura was used in combination with four traditional Chinese medicine herbs: astragalus membranaceus, ligustrum lucidum, angelica sinensis, and glycyrrhiza uralensis. 48“S180” mice were randomly assigned to four groups:group Ⅰ, control group;group Ⅱ,5Fu alone;group Ⅲ,5Fu combined with Batilole;grpup Ⅳ,5Fu combined with Astragulus membranaceus mistura. We determined the changes by peripheral blood indices. The percentage of lymphocyte transformation was detecled by lymphocyte transformation test. Macrophage phagocytosis was detected with Neutral Red Dye Uptake method hemopoietic microenvironment for bone marrow was studied under TEM. The incidence of toxication caused by chemotherapy, leukocytopenia and thrombocytopenia were observed. The results: the leukocyte and platelet counts were much more in group Ⅳ than in other groups (P<0.01);the macrophage phagocytotic ability and lymphocyte transformation percentage were significantly higher in group Ⅳ in other groups (P<0.01). Conclusion: Astragalus membranaceus mistura could overcome the toxicity of cancer chemotherapy in hematopoietic system. This therapy was effective in modulating myelosuppression induced by chemotherapy. Astragalus membranaceus mistura was effective for the enhancement of cellular immune response, and was able to improve the function of both lymphocytes and macrophages. Astragalus membranaceus mistura could protect reticulocyte and monocytemacrophage from impairment caused by chemotherapy.